CLINICAL CASE STUDIES

Interpreting Epigenetic Biomarkers in Patients

Real-world examples of how TruAge™ and TruHealth™ results translate patients’ epigenetic patterns into clinical action.

CLINICAL CASE 01

When Standard Labs Miss Disease

A fit, symptom-free 46-year-old man wanted to optimize his health. His routine labs looked reassuring. But the epigenetic biomarkers in his TruAge and TruHealth results revealed a hidden atherogenic pattern.
‍
Follow-up testing that he'd never have done otherwise confirmed dyslipidemia, and a CT angiogram showed coronary plaque.
‍
Standard screening missed these subtle shifts in the patient’s biology. Epigenetics detected cardiovascular disease years before symptoms would have been felt.

CLINICAL CASE 02

When Habits Quietly Add Up

A 39-year-old woman identifies as "busy but healthy" – two kids, jogging 2–3x/week, and a low-calorie, high-protein diet.
‍
Her TruAge and TruHealth results detected elevated biomarkers: alcohol exposure, triglycerides, and phenylacetylglutamine (PAG), pointing to early cardiometabolic and gut-health risk.
‍
Standard intake would have missed these nuances. Epigenetics caught the modifiable risk before it became a diagnosis – prompting repeat labs, a renal function check, and targeted diet and alcohol changes she started before her next visit.

INTERPRETIVE FRAMEWORK

4-Step Approach to Interpreting Epigenetic Reports

Applicable across TruAge and TruHealth reports for any patient profile

Consider Context at Collection

Was the patient's biology in a stable state? Recent infection, surgery, medication changes, or dramatic lifestyle shifts can move epigenetic signals.

Use Biological Ages for Orientation

Aging clocks are headlines, not conclusions. Younger biological age suggests optimization; older suggests more systemic concern. Don't act on clocks alone.

Read for Themes & Patterns

Two or more signals converging on the same pathway = treat as real until proven otherwise. One isolated marker = hypothesis only. Cross-reference TruAge and TruHealth together.

Convert Signals to a Treatment Plan

Verify epigenetic signals with conventional labs and clinical history. Introduce targeted interventions. Retest at 3–6 months. Monitor trajectory over absolute values.